Te CC, Vemulapalli S, Confer SD, et al. Recurrent malignant melanoma of the penis[J]. Urology, 2008, 72(5): 1185. e15-e16.

Van Geel AN, Den Bakker MA, Kirkels W, et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature[J]. Urology, 2007, 70(1): 143-147. doi: 10.1016/j.urology.2007.03.039

Jabiles AG, Del Mar EY, Perez GAD, et al. Penile melanoma: a 20-Year analysis of six patients at the National Cancer Institute of Peru, Lima[J]. Ecancermedicalscience, 2017, 11: 731-731.

Bechara GR, Schwindt AB, Ornellas AA, et al. Penile primary melanoma: analysis of 6 patients treated at Brazilian National Cancer Institute in the last eight years[J]. Int Braz J Urol, 2013, 39(6): 823-831. doi: 10.1590/S1677-5538.IBJU.2013.06.08

Brady KL, Mercurio MG, Brown MD. Malignant tumors of the penis[J]. Dermatol Surg, 2013, 39(4): 527-547. doi: 10.1111/dsu.12029

Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification[J]. J Clin Oncol, 2009, 27(36): 6199-6206. doi: 10.1200/JCO.2009.23.4799

De Giorgi V, Grazzini M, Massi D, et al. Melanoma of the penis: a clinical dermoscopic case study[J]. Acta Derm Venereol, 2010, 90(1): 87-88. doi: 10.2340/00015555-0705

Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma[J]. J Clin Oncol, 2013, 31(35): 4387-4393. doi: 10.1200/JCO.2013.50.1114

Hankins CL, Kotwal S, Majumder S, et al. Multifocal melanoma of the glans penis[J]. Plast Reconstr Surg, 2006, 118(2): 33e-38e. doi: 10.1097/01.prs.0000227611.75887.50

Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme[J]. Lancet, 1998, 351(9105): 793-796. doi: 10.1016/S0140-6736(97)08260-3

Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial[J]. Lancet Oncol, 2016, 17(2): 184-192. doi: 10.1016/S1470-2045(15)00482-9

Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy(ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1049-1060. doi: 10.1016/S1470-2045(15)00187-4

Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage ⅡB-Ⅲ melanoma: results of intergroup trial E1694/S9512/C509801[J]. J Clin Oncol, 2001, 19(9): 2370-2380. doi: 10.1200/JCO.2001.19.9.2370

Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190[J]. J Clin Oncol, 2000, 18(12): 2444-2458. doi: 10.1200/JCO.2000.18.12.2444

Stillwell TJ, Zincke H, Gaffey TA, et al. Malignant melanoma of the penis[J]. J Urol, 1988, 140(1): 72-75. doi: 10.1016/S0022-5347(17)41490-X

Oldbring J, Mikulowski P. Malignant melanoma of the penis and male urethra. Report of nine cases and review of the literature[J]. Cancer, 1987, 59(3): 581-587. doi: 10.1002/1097-0142(19870201)59:3<581::AID-CNCR2820590338>3.0.CO;2-#